Compare Gilead Sciences, Inc. (GILD) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Packaging Corporation of America — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Packaging Corporation of America trades at $231.22 (market cap $20.49B). The key difference: Gilead Sciences, Inc. is far larger — about 8.9× Packaging Corporation of America's market cap, and Packaging Corporation of America pays the higher dividend (2.61%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Packaging Corporation of America for 45 Days on average.
| GILD | PKG | |
|---|---|---|
Market Cap | $182.40B | $20.49B |
Volume | 4,469,821 | 493,499 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $257.43 |
52-Week Low | $116.74 | $191.68 |
Typical Hold Time | 111 Days | 45 Days |
Enterprise Value | $205.46B | $24.30B |
Dividend Yield | 2.23% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Packaging Corporation of America (PKG) trades at $227.25, down 1.08% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with Q2 2026 beating estimates but net income margin projected to decline in 2026. Analyst consensus is a Buy with a $272.43 price target, though technical indicators suggest near-term pressure with support at $225.
PKG offers a stable dividend and benefits from consistent packaging demand, but faces headwinds from cost pressures and negative cash flow. Investment appeal hinges on execution against margin challenges and the upcoming Q3 earnings report. Risks include rising input costs and competitive pressures in the industrial packaging sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
